Filing Flows › Comparisons › BOLT vs BDPT
Bolt Biotherapeutics vs Bioadaptives: BOLT and BDPT compared
Bolt Biotherapeutics is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $5K for Bioadaptives (Q2 2026). Bioadaptives is growing faster (+55% against -100% a year earlier).
Where the money goes: BOLT and BDPT
Bolt Biotherapeutics (BOLT) · Q2 2026
Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Bioadaptives (BDPT) · Q2 2026
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart follows the revenue to costs, profit and cash.
| Bolt Biotherapeutics (BOLT) | Bioadaptives (BDPT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5K | $5K |
| Revenue growth, Y/Y | -100% | +55% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.7M | $150K |
| Operating cash flow | −$6.5M | −$44K |
Questions
Which is bigger, Bolt Biotherapeutics or Bioadaptives?
Bolt Biotherapeutics is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $5K for Bioadaptives (Q2 2026).
Is Bolt Biotherapeutics or Bioadaptives growing faster?
Bioadaptives is growing faster (+55% against -100% a year earlier).
More: Bolt Biotherapeutics earnings · how Bolt Biotherapeutics makes money · Bioadaptives earnings · how Bioadaptives makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.